The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Increasing the efficacy of PD-1 inhibitors in HL using combination strategies
David Bond, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, summarizes various combination approaches being explored with PD-1 inhibitors for the treatment of Hodgkin lymphoma (HL), including combinations with LAG-3 inhibitors, chemotherapy, and antibody-drug conjugates (ADCs). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
